<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04739930</url>
  </required_header>
  <id_info>
    <org_study_id>17121805</org_study_id>
    <nct_id>NCT04739930</nct_id>
  </id_info>
  <brief_title>Autologous Bone Marrow Concentrate in Knee Osteochondral Allograft Transplantation</brief_title>
  <official_title>Prospective, Randomized, Single Blind Clinical Trial to Investigate the Impact of Autologous Bone Marrow Concentrate in Knee Osteochondral Allograft Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Joint Restoration Foundation (JRF)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to establish if mesenchymal stem cell augmentation improves graft&#xD;
      incorporation and to analyze the cytokine environment of the joint after osteochondral&#xD;
      allograft transplantation (OCA) with and without intra-articular bone marrow aspirate&#xD;
      concentrate (BMAC) injection. Information learned from this study can be used to&#xD;
      biochemically compare treatment response and to assess emerging therapeutic options that may&#xD;
      positively alter the biochemical environment in patients who suffer from articular cartilage&#xD;
      disorders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Articular cartilage injuries in the knee continue to grow in number as detection and&#xD;
      treatment options have advanced. Treatment options, including microfracture, autologous&#xD;
      chondrocyte (cells that make cartilage) implantation, osteochondral grafting and meniscus&#xD;
      transplantation can hopefully deter the progression of degeneration and have promise to&#xD;
      function as disease modifying solutions. Osteochondral allograft transplantation (OCA) has&#xD;
      emerged as a preferred method of treating large focal chondral defects as it structurally&#xD;
      replaces the cartilage and often involved sub-chondral bone with native hyaline cartilage and&#xD;
      bone. The results of OCA are successful with greater than 85% survival at 5-year follow-up.&#xD;
      Failure can occur due to a lack of boney integration or low chondrocyte viability. Therefore,&#xD;
      anything to enhance the graft augmentation process may be useful in preventing failure. The&#xD;
      purpose of this prospective, randomized study is to determine the effect of bone marrow&#xD;
      aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells on&#xD;
      improving graft incorporation and preventing failure. The effect of BMAC on the graft and&#xD;
      intra-articular knee environment will be evaluated using 3 techniques: computed tomography&#xD;
      (CT) imaging, synovial fluid cytokine analysis, and serum biomarker analysis. Information&#xD;
      learned from this study can be used to biochemically compare treatment response and to assess&#xD;
      emerging therapeutic options that may positively alter the biochemical environment in&#xD;
      patients undergoing osteochondral allograft transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, Randomized, Single Blind Clinical Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The control group will receive a 0.5cm sham incision over the iliac crest, but bone marrow aspiration will not be performed.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Synovial Fluid Cytokine Measurement</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>To measure the amount of cytokines and cartilage biomarkers in the synovial fluid of patients undergoing osteochondral allograft transplantation with and without BMAC augmentation at different time points</description>
  </primary_outcome>
  <other_outcome>
    <measure>Radiographic analysis</measure>
    <time_frame>Day 1, Post-operative 2 weeks, 6 weeks, 12, weeks, 24 weeks, 52 weeks</time_frame>
    <description>Changes in graft status will be analysed using radiographic analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Computed Tomography (CT) analysis</measure>
    <time_frame>Post-operative 24 weeks</time_frame>
    <description>Changes in graft status will be analysed using Computed Tomography (CT) analysis</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cartilage Injury</condition>
  <arm_group>
    <arm_group_label>Bone Marrow Aspiration Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A bone marrow aspiration will be performed from the iliac crest. The bone marrow aspirate will be processed using a bone marrow aspirate concentrate (BMAC) harvesting system. The osteochondral allograft plug will then be soaked in the BMAC for a minimum 2 minutes prior to implantation. The remaining BMAC will be placed in the defect site prior to plug implantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The control group will receive a 0.5cm sham incision over the iliac crest, but bone marrow aspiration will not be performed. The osteochondral allograft plug will not be soaked in BMAC prior to implantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous bone marrow aspirate will be harvested and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to site of operation</intervention_name>
    <description>Autologous bone marrow aspirate will be processed and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to the site of operation in the treatment group</description>
    <arm_group_label>Bone Marrow Aspiration Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Control group incision</intervention_name>
    <description>0.5cm sham incision over the iliac crest</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        â€¢ Patients aged 18-50 with a cartilage defect indicated for treatment with osteochondral&#xD;
        allograft&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with known rheumatoid arthritis, any other inflammatory arthropathy or&#xD;
             synovial tissue disorder.&#xD;
&#xD;
          -  Patients with known bipolar osteoarthritis of the knee as determined by the treating&#xD;
             physician, greater than Kellegren-Lawrence Grade 3 on x-ray imaging&#xD;
&#xD;
          -  Patient with a known infection or history of infection in the affected knee&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Yanke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adam Yanke</last_name>
    <phone>(312) 563-5735</phone>
    <email>adam.yanke@rushortho.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla M Edwards, PhD</last_name>
      <phone>312-563-5735</phone>
      <email>carla_edwards@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Brian J Cole, MD, MBA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adam B Yanke, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brain Forsythe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 24, 2020</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form: HIPAA Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT04739930/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 31, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT04739930/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Main Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 31, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT04739930/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

